Nintedanib slows the rate of decline in forced vital capacity (FVC) in patients with progressive fibrosing RA associated interstitial lung disease (RA-ILD), according to a UK study. A subanalysis of the INBUILD trial comprised 89 patients with RA-ILD of which 42 were randomised to nintedanib and 47 to placebo. Most were male (61%), current or ...
Antifibrotic agent slows progression of RA-ILD
By Mardi Chapman
16 Jun 2021